OBJECTIVE: Numerous studies have evaluated the prevalence and importance of vitamin D deficiency among patients with chronic kidney disease and end-stage renal disease; however, little is known about vitamin D levels in acute kidney injury (AKI). We evaluated the association between vitamin D metabolites and clinical outcomes among patients with AKI. DESIGN: Prospective cohort study. PATIENTS: A total of 30 participants with AKI and 30 controls from general hospital wards and intensive care units at a tertiary care hospital were recruited for the study. MEASUREMENTS: Plasma levels of 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)2 D], 24R,25-dihydroxyvitamin D3 , vitamin D binding protein (VDBP) and fibroblast growth factor 23 (FGF23) were measured within 24 hours of AKI onset and 5 days later. Bioavailable 25(OH)D and 1,25(OH)2 D levels, defined as the sum of free- and albumin-bound 25(OH)D and 1,25(OH)2 D, were estimated using equations. RESULTS: Compared to controls, participants with AKI had lower levels of 1,25(OH)2 D [17 (10-22) vs 25 (15-35) pg/ml, P = 0·01], lower levels of VDBP [23 (15-31) vs 29 (25-36) mg/dl, P = 0·003] and similar levels of bioavailable 25(OH)D and 1,25(OH)2 D at enrolment. Levels of bioavailable 25(OH)D were inversely associated with severity of sepsis in the overall sample (P < 0·001). Among participants with AKI, bioavailable 25(OH)D, but not other vitamin D metabolites, was significantly associated with mortality after adjusting for age and serum creatinine (adjusted odds ratio per 1 SD ln [bioavailable 25(OH)D] = 0·16, 95% confidence interval = 0·03-0·85). CONCLUSIONS: Bioavailable 25(OH)D could have a role as a biomarker or mediator of adverse outcomes among patients with established AKI.
OBJECTIVE: Numerous studies have evaluated the prevalence and importance of vitamin Ddeficiency among patients with chronic kidney disease and end-stage renal disease; however, little is known about vitamin D levels in acute kidney injury (AKI). We evaluated the association between vitamin D metabolites and clinical outcomes among patients with AKI. DESIGN: Prospective cohort study. PATIENTS: A total of 30 participants with AKI and 30 controls from general hospital wards and intensive care units at a tertiary care hospital were recruited for the study. MEASUREMENTS: Plasma levels of 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)2 D], 24R,25-dihydroxyvitamin D3 , vitamin D binding protein (VDBP) and fibroblast growth factor 23 (FGF23) were measured within 24 hours of AKI onset and 5 days later. Bioavailable 25(OH)D and 1,25(OH)2 D levels, defined as the sum of free- and albumin-bound 25(OH)D and 1,25(OH)2 D, were estimated using equations. RESULTS: Compared to controls, participants with AKI had lower levels of 1,25(OH)2 D [17 (10-22) vs 25 (15-35) pg/ml, P = 0·01], lower levels of VDBP [23 (15-31) vs 29 (25-36) mg/dl, P = 0·003] and similar levels of bioavailable 25(OH)D and 1,25(OH)2 D at enrolment. Levels of bioavailable 25(OH)D were inversely associated with severity of sepsis in the overall sample (P < 0·001). Among participants with AKI, bioavailable 25(OH)D, but not other vitamin D metabolites, was significantly associated with mortality after adjusting for age and serum creatinine (adjusted odds ratio per 1 SD ln [bioavailable 25(OH)D] = 0·16, 95% confidence interval = 0·03-0·85). CONCLUSIONS: Bioavailable 25(OH)D could have a role as a biomarker or mediator of adverse outcomes among patients with established AKI.
Authors: Georges Saab; Daniel O Young; Yekaterina Gincherman; Karla Giles; Kathryn Norwood; Daniel W Coyne Journal: Nephron Clin Pract Date: 2007-01-16
Authors: Philip T Liu; Steffen Stenger; Huiying Li; Linda Wenzel; Belinda H Tan; Stephan R Krutzik; Maria Teresa Ochoa; Jürgen Schauber; Kent Wu; Christoph Meinken; Diane L Kamen; Manfred Wagner; Robert Bals; Andreas Steinmeyer; Ulrich Zügel; Richard L Gallo; David Eisenberg; Martin Hewison; Bruce W Hollis; John S Adams; Barry R Bloom; Robert L Modlin Journal: Science Date: 2006-02-23 Impact factor: 47.728
Authors: Neha M Patel; Orlando M Gutiérrez; Dennis L Andress; Daniel W Coyne; Adeera Levin; Myles Wolf Journal: Kidney Int Date: 2010-02-03 Impact factor: 10.612
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: David E Leaf; Anas Raed; Michael W Donnino; Adit A Ginde; Sushrut S Waikar Journal: Am J Respir Crit Care Med Date: 2014-09-01 Impact factor: 21.405
Authors: Sadeq A Quraishi; Gennaro De Pascale; Joseph S Needleman; Harumasa Nakazawa; Masao Kaneki; Ednan K Bajwa; Carlos A Camargo; Ishir Bhan Journal: Crit Care Med Date: 2015-09 Impact factor: 7.598
Authors: David E Leaf; Kirolos A Jacob; Anand Srivastava; Margaret E Chen; Marta Christov; Harald Jüppner; Venkata S Sabbisetti; Aline Martin; Myles Wolf; Sushrut S Waikar Journal: J Am Soc Nephrol Date: 2016-12-27 Impact factor: 10.121
Authors: Sadeq A Quraishi; Edward A Bittner; Livnat Blum; Caitlin M McCarthy; Ishir Bhan; Carlos A Camargo Journal: Crit Care Med Date: 2014-06 Impact factor: 7.598
Authors: Alan S Go; Chi-Yuan Hsu; Jingrong Yang; Thida C Tan; Sijie Zheng; Juan D Ordonez; Kathleen D Liu Journal: Clin J Am Soc Nephrol Date: 2018-05-17 Impact factor: 8.237
Authors: Jonathan M Mansbach; Kohei Hasegawa; Nadim J Ajami; Joseph F Petrosino; Pedro A Piedra; Courtney N Tierney; Janice A Espinola; Carlos A Camargo Journal: Clin Infect Dis Date: 2017-09-15 Impact factor: 9.079